Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Recruiting 7Completed 3Not yet recruiting 2Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neuroblastoma 2Osteosarcoma 1

Interventions

Cyclophosphamide 10Magnetic Resonance Spectroscopy 8Temozolomide 6Biopsy 6dinutuximab 5X-Rays 5Topotecan 5Specimen Handling 5Phantoms, Imaging 5Nuclear Medicine Department, Hospital 5Irinotecan 5Etoposide 3Colony-Stimulating Factors 3ulixertinib 2tipifarnib 2selpercatinib 2sargramostim 2pembrolizumab 2palbociclib 2naxitamab 2larotrectinib 2ivosidenib 2fludarabine phosphate 2fludarabine 2etoposide phosphate 2erdafitinib 2ensartinib 2Lenalidomide 2Isotretinoin 2Granulocyte-Macrophage Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Neuroblastoma × naxitamab × Clear all
NCT01757626 2026-01-07

Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma

Memorial Sloan Kettering Cancer Center

Phase 1/2 Active not recruiting
186 enrolled 1 FDA
CNS

Neuroblastoma

NCT03189706 2025-07-02

Study of Chemoimmunotherapy for High-Risk Neuroblastoma

Memorial Sloan Kettering Cancer Center

Phase EARLY_PHASE1 Active not recruiting
48 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡